The Medicare program has expanded access to continuous glucose monitoring systems like the FreeStyle Libre 2 system and the FreeStyle Libre 14 day system for insulin-using Medicare beneficiaries with diabetes, removing the prior requirement of multiple daily insulin injections. Medicare beneficiaries with diabetes and a history of problematic hypoglycemia may also be eligible to have their FreeStyle Libre 2 system or FreeStyle Libre 14 day system covered for reimbursement. Abbott is working to get the latest-generation FreeStyle Libre 3 system added to Medicare’s list of covered systems as soon as possible.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABT:
- Abbott price target lowered to $116 from $123 at Raymond James
- Abbott Laboratories (ABT) Q1 Earnings Cheat Sheet
- Abbott says FDA clears reader for FreeStyle Libre 3 system
- Needham med tech analysts to hold an analyst/industry conference call
- Abbott says no FreeStyle Libre readers being physically recalled
